Don’t Give In To Big Pharma On Drug Pricing | Letters

While nan main executive of Eli Lilly whitethorn lament nan UK’s supplier prices (UK is ‘worst state successful Europe’ for supplier prices, says Mounjaro maker, 24 September), nan NHS should observe them. The strategy put successful spot for evaluating nan cost-effectiveness of caller narcotics is respected nan world complete and is successful successful applying nan rule that backing a caller merchandise should not harm nan NHS arsenic a whole. This rule of cost-effectiveness has led to wide value reductions for nan NHS that has allowed nan work arsenic a full to benefit.

The main executive of Eli Lilly links nan caller pausing aliases cancelling of pharmaceutical manufacture investments successful nan UK to supplier pricing here, erstwhile these are down to the supplier companies’ desperation to kowtow to Donald Trump.

Further to this, nan talk of expanding Nice’s cost-effectiveness threshold, and moreover index-linking this, is simply a ugliness (NHS could salary 25% much for medicines nether scheme to extremity statement pinch drugmakers and Trump, 8 October). The period is not a value that we should summation each year; it is simply a measurement of opportunity cost. It measures what wellness improvements successful nan wider NHS we miss retired connected erstwhile we put much successful a caller work aliases drug. If a caller supplier doesn’t make much “health” than that which it displaces, nan NHS arsenic a full is worse off. The complaint of displacement doesn’t directly change pinch inflation. Linking nan 2 is nonsense.
Simon Dixon
Former professor of wellness economics, University of Sheffield